Panchsheel Organic Ltd.
BSE: PANCHSHEEL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Panchsheel Organic Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Panchsheel Organics Ltd is a manufacturer and exporter of bulk drugs, pharmaceutical intermediates, and finished formulations for human and veterinary use. The company also maintains a diverse portfolio spanning nutraceuticals, hormones, steroids, and agricultural biotechnology products.
Business Model
The company generates revenue through the manufacturing and sale of pharmaceutical APIs and intermediates, alongside specialized products for the aquaculture and agri-biotech sectors. It operates as a WHO-compliant, ISO, and GMP-certified entity, leveraging its manufacturing capabilities to serve both domestic and international markets.
- Incorporation Year:1990
Growth Outlook
Growth is expected to be driven by the company's diversified product range, including its expansion into the agri-biotech and aquaculture segments. Continued adherence to international quality standards like WHO and GMP certifications supports its export-oriented business strategy.
Key Risks
- Regulatory Compliance Risk. Failure to maintain stringent WHO, ISO, and GMP certifications could lead to the suspension of manufacturing operations or export bans.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and active pharmaceutical ingredients can significantly impact profit margins.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency fluctuations that may affect the competitiveness and profitability of its international sales.
- Sectoral Competition. The pharmaceutical and bulk drug industry is highly competitive, requiring constant investment in R&D to maintain market share against larger domestic and global players.
Start your research today
Unlock AI insights, financials, peers and live data on Panchsheel Organic Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹107 Cr
TTM · standalone
NET PROFIT
₹11 Cr
TTM · standalone
EPS
₹8.22
TTM · standalone
RETURN ON EQUITY
8.0%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
10.5%
TTM · standalone
P/E
14.4x
Q4 FY26 · standalone
EV/EBITDA
7.4x
Q4 FY26 · standalone
EBITDA MARGIN
16.0%
TTM · standalone
NET PROFIT MARGIN
5.5%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Panchsheel Organic Ltd.PANCHSHEEL | ₹154 Cr | 14.18 | 9.12 | -5.6% | 16.0% | 8.0% | 10.5% | -22.8% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Panchsheel Organic Ltd.
BSE: PANCHSHEEL · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Panchsheel Organic Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Panchsheel Organics Ltd is a manufacturer and exporter of bulk drugs, pharmaceutical intermediates, and finished formulations for human and veterinary use. The company also maintains a diverse portfolio spanning nutraceuticals, hormones, steroids, and agricultural biotechnology products.
Business Model
The company generates revenue through the manufacturing and sale of pharmaceutical APIs and intermediates, alongside specialized products for the aquaculture and agri-biotech sectors. It operates as a WHO-compliant, ISO, and GMP-certified entity, leveraging its manufacturing capabilities to serve both domestic and international markets.
- Incorporation Year:1990
Growth Outlook
Growth is expected to be driven by the company's diversified product range, including its expansion into the agri-biotech and aquaculture segments. Continued adherence to international quality standards like WHO and GMP certifications supports its export-oriented business strategy.
Key Risks
- Regulatory Compliance Risk. Failure to maintain stringent WHO, ISO, and GMP certifications could lead to the suspension of manufacturing operations or export bans.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and active pharmaceutical ingredients can significantly impact profit margins.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency fluctuations that may affect the competitiveness and profitability of its international sales.
- Sectoral Competition. The pharmaceutical and bulk drug industry is highly competitive, requiring constant investment in R&D to maintain market share against larger domestic and global players.
Start your research today
Unlock AI insights, financials, peers and live data on Panchsheel Organic Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹107 Cr
TTM · standalone
NET PROFIT
₹11 Cr
TTM · standalone
EPS
₹8.22
TTM · standalone
RETURN ON EQUITY
8.0%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
10.5%
TTM · standalone
P/E
14.4x
Q4 FY26 · standalone
EV/EBITDA
7.4x
Q4 FY26 · standalone
EBITDA MARGIN
16.0%
TTM · standalone
NET PROFIT MARGIN
5.5%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26